Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375200 | 0.93 | MME (0.53) | MMEPSMB5ANPEPCTSSCTSK | |
| SCHEMBL17994254 | 0.89 | PTPN1 (0.55) | MMECTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL14297648 | 0.88 | CTSS (0.60) | MMEPSMB5ANPEPCTSSCTSK | |
| SCHEMBL10119263 | 0.88 | CTSS (0.60) | MMEPSMB5ANPEPCTSSCTSK | |
| SCHEMBL17994244 | 0.88 | PSMB5 (0.47) | PSMB5CTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL17994243 | 0.87 | HSPA5 (0.50) | MMEANPEPCTSL | |
| SCHEMBL7318555 | 0.84 | PSMB5 (0.65) | MMEPSMB5CTSSCTSKCTSB | |
| SCHEMBL10119250 | 0.84 | PSMB5 (0.65) | MMEPSMB5CTSSCTSKCTSB | |
| SCHEMBL16305972 | 0.83 | L3MBTL1 (0.45) | MMEANPEPCTSSCTSKCTSB | |
| SCHEMBL17994241 | 0.83 | L3MBTL1 (0.57) | CTSSCTSKCTSBL3MBTL1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MME 796/4885PSMB5 3434/4885ANPEP 305/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MME 796/4885PSMB5 3434/4885ANPEP 305/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | MME 919/4885PSMB5 3810/4885ANPEP 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.